🧪
hypothesis

GluN2B Tonic Activity Suppresses Glymphatic Perfusion Via Vasomotion Dysregulation

Hypothesis

GluN2B Tonic Activity Suppresses Glymphatic Perfusion Via Vasomotion Dysregulation

REVISED MECHANISM (post-Skeptic critique): Constitutive GluN2B signaling combined with age-related oxidative stress leads to excessive nNOS-derived superoxide and peroxynitrite (ONOO⁻) formation, causing vasomotor uncoupling, AQP4 oxidat.
🧬 GRIN2B (thalamocortical projection neurons); downstream: NOS1, AQP4🩺 neuroscience🎯 Composite 70%💱 $0.59▼14.5%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 2 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.62 (15%) Evidence 0.68 (15%) Novelty 0.70 (12%) Feasibility 0.72 (12%) Impact 0.78 (12%) Druggability 0.72 (10%) Safety 0.65 (8%) Competition 0.70 (6%) Data Avail. 0.75 (5%) Reproducible 0.68 (5%) KG Connect 0.50 (8%) 0.700 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite70%

🧪 Overview

REVISED MECHANISM (post-Skeptic critique): Constitutive GluN2B signaling combined with age-related oxidative stress leads to excessive nNOS-derived superoxide and peroxynitrite (ONOO⁻) formation, causing vasomotor uncoupling, AQP4 oxidation, and endothelial glycocalyx damage. Original NO-vasoconstriction mechanism was mechanistically flawed (NO produces vasodilation). Memantine data explained by reduced excitotoxic oxidative stress. Targeting downstream astrocyte/vascular pathways may be superior to direct GluN2B inhibition.

🧬 Mechanism

🔗 Mechanism from KG for GRIN2B (thalamocortical projection neurons); downstream: NOS1, AQP4

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    GluN2B["GluN2B"] -->|regulates| thalamic_burst_firing["thalamic burst firing"]
    slow_wave_oscillations["slow-wave oscillations"] -->|enhances| glymphatic_clearance["glymphatic_clearance"]
    tau_pathology["tau_pathology"] -.->|inhibits| glymphatic_clearance_effi["glymphatic clearance efficiency"]
    Trem2["Trem2"] -->|regulates| tau_phagocytosis["tau phagocytosis"]
    TREM2_deficiency["TREM2 deficiency"] -->|associated with| Tau_Clearance["Tau Clearance"]
    Cx3Cl1["Cx3Cl1"] -->|associated with| Cx3Cr1["Cx3Cr1"]
    Cx3Cr1_1["Cx3Cr1"] -->|regulates| tau_phagocytosis_2["tau phagocytosis"]
    Memantine["Memantine"] -->|enhances| CSF_tracer_clearance["CSF tracer clearance"]
    GluN2B_3["GluN2B"] -->|associated with| cortical_slow_wave_oscill["cortical slow-wave oscillations"]
    oxidative_stress["oxidative_stress"] -->|causes| AQP4_oxidation["AQP4 oxidation"]
    GLUTAMATE_EXCITOTOXICITY["GLUTAMATE EXCITOTOXICITY"] -->|enhances| Tau_Secretion["Tau Secretion"]
    sess_SRB_2026_04_28_h_var["sess_SRB-2026-04-28-h-var-e2b5a7e7db_task_9aae8fc5"] -->|causal extracted| processed["processed"]
    style GluN2B fill:#4fc3f7,stroke:#333,color:#000
    style thalamic_burst_firing fill:#4fc3f7,stroke:#333,color:#000
    style slow_wave_oscillations fill:#4fc3f7,stroke:#333,color:#000
    style glymphatic_clearance fill:#81c784,stroke:#333,color:#000
    style tau_pathology fill:#ef5350,stroke:#333,color:#000
    style glymphatic_clearance_effi fill:#4fc3f7,stroke:#333,color:#000
    style Trem2 fill:#4fc3f7,stroke:#333,color:#000
    style tau_phagocytosis fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_deficiency fill:#4fc3f7,stroke:#333,color:#000
    style Tau_Clearance fill:#4fc3f7,stroke:#333,color:#000
    style Cx3Cl1 fill:#4fc3f7,stroke:#333,color:#000
    style Cx3Cr1 fill:#4fc3f7,stroke:#333,color:#000
    style Cx3Cr1_1 fill:#4fc3f7,stroke:#333,color:#000
    style tau_phagocytosis_2 fill:#4fc3f7,stroke:#333,color:#000
    style Memantine fill:#ce93d8,stroke:#333,color:#000
    style CSF_tracer_clearance fill:#ce93d8,stroke:#333,color:#000
    style GluN2B_3 fill:#4fc3f7,stroke:#333,color:#000
    style cortical_slow_wave_oscill fill:#4fc3f7,stroke:#333,color:#000
    style oxidative_stress fill:#4fc3f7,stroke:#333,color:#000
    style AQP4_oxidation fill:#4fc3f7,stroke:#333,color:#000
    style GLUTAMATE_EXCITOTOXICITY fill:#4fc3f7,stroke:#333,color:#000
    style Tau_Secretion fill:#4fc3f7,stroke:#333,color:#000
    style sess_SRB_2026_04_28_h_var fill:#4fc3f7,stroke:#333,color:#000
    style processed fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix2 supports3 contradicts
Supports
Memantine enhances CSF tracer clearance in mice (mechanism reinterpreted)
PMID:29654327
Supports
GluN2B upregulation in aged cortex correlates with reduced glymphatic influx
PMID:32284313
Contradicts
NO produces vasodilation, not vasoconstriction; original mechanism mechanistically unsound
PMID:N/A
Contradicts
Ifenprodil has off-target effects on alpha1-adrenergic and sigma receptors
PMID:N/A
Contradicts
Memantine citation may be mismatched (per Skeptic)
PMID:N/A
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — GRIN2B

🧬 PDB 7EU8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GRIN2B (thalamocortical projection neurons); downstream: NOS1, AQP4 →

No DepMap CRISPR Chronos data found for GRIN2B (thalamocortical projection neurons); downstream: NOS1, AQP4.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.1%
Volatility
Low
0.0024
Events (7d)
3
Price History
▼14.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF aged thalamocortical projection neuron-specific GluN2B-overexpressing transgenic mice (CaMKII-Cre;GRIN2B-OE) are treated with either direct GluN2B antagonist (ifenprodil, 5 mg/kg, s.c., 14 days) ORAQP4-MitoQ group: glymphatic clearance rate increases from baseline 0.015 min⁻¹ to ≥0.021 min⁻¹; ifenprodil group: clearance rate increases to ≤0.018 min⁻¹; sig— no observation —pending0.55
IF aged (18-24 month) C57BL/6 mice with constitutive GluN2B overactivity receive selective nNOS inhibitor (ARL 17477, 10 mg/kg, i.p., 7 days) THEN glymphatic CSF influx into the cortex (measured by inSignificant increase in paravascular CSF tracer clearance rate (k_clearance) from 0.02 min⁻¹ baseline to ≥0.026 min⁻¹, with corresponding reduction in cortical — no observation —pending0.65
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF aged (18-24 month) C57BL/6 mice with constitutive GluN2B overactivity receive selective nNOS inhibitor (ARL 17477, 10 mg/kg, i.p., 7 days) THEN glymphatic CSF influx into the cortex (measured by in vivo 2-photon imaging of subarachnoid CSF- tracer AlexaFluor-647 conjugated albumin) will increase
Predicted outcome: Significant increase in paravascular CSF tracer clearance rate (k_clearance) from 0.02 min⁻¹ baseline to ≥0.026 min⁻¹, with corresponding reduction in
Falsification: No significant change in glymphatic tracer influx (<10% difference from vehicle) despite confirmed nNOS inhibition (assessed by reduced cerebellar nNOS activity via ELISA or reduced nitrite levels in
pendingconf 55%
IF aged thalamocortical projection neuron-specific GluN2B-overexpressing transgenic mice (CaMKII-Cre;GRIN2B-OE) are treated with either direct GluN2B antagonist (ifenprodil, 5 mg/kg, s.c., 14 days) OR downstream AQP4 oxidation protection (MitoQ, 10 mg/kg, i.p., 14 days) THEN downstream AQP4 protecti
Predicted outcome: AQP4-MitoQ group: glymphatic clearance rate increases from baseline 0.015 min⁻¹ to ≥0.021 min⁻¹; ifenprodil group: clearance rate increases to ≤0.018
Falsification: Falsified if ifenprodil produces equal or greater glymphatic improvement (>35% restoration) compared to MitoQ, OR if neither intervention produces significant improvement (>15% change from baseline),
View on SciDEX ↗